CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Talis Biomedical Corporation - TLIS CFD

    7.66
    1.06%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.22
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Talis Biomedical Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 7.58
    Open* 7.35
    1-Year Change* 1341.18%
    Day's Range* 7.27 - 7.91
    52 wk Range 4.35-9.75
    Average Volume (10 days) 51.57K
    Average Volume (3 months) 295.38K
    Market Cap 12.97M
    P/E Ratio -100.00K
    Shares Outstanding 1.82M
    Revenue 2.20M
    EPS -41.90
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Mar 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 7.66 0.31 4.22% 7.35 7.91 7.26
    Nov 30, 2023 7.58 0.40 5.57% 7.18 7.72 7.17
    Nov 29, 2023 7.40 -0.11 -1.46% 7.51 7.51 7.16
    Nov 28, 2023 7.34 -0.03 -0.41% 7.37 7.53 7.22
    Nov 27, 2023 7.34 0.36 5.16% 6.98 7.45 6.98
    Nov 24, 2023 6.87 -0.12 -1.72% 6.99 7.11 6.87
    Nov 22, 2023 6.99 0.03 0.43% 6.96 7.18 6.87
    Nov 21, 2023 6.97 -0.20 -2.79% 7.17 7.40 6.81
    Nov 20, 2023 7.13 0.29 4.24% 6.84 7.47 6.82
    Nov 17, 2023 7.00 0.28 4.17% 6.72 7.08 6.72
    Nov 16, 2023 6.97 0.09 1.31% 6.88 7.00 6.61
    Nov 15, 2023 7.05 0.20 2.92% 6.85 7.09 6.82
    Nov 14, 2023 7.02 0.33 4.93% 6.69 7.25 6.69
    Nov 13, 2023 5.28 -0.20 -3.65% 5.48 5.48 5.19
    Nov 10, 2023 5.56 0.00 0.00% 5.56 5.59 5.56
    Nov 9, 2023 5.62 0.06 1.08% 5.56 5.62 5.56
    Nov 8, 2023 5.78 -0.12 -2.03% 5.90 5.90 5.78
    Nov 7, 2023 6.05 0.20 3.42% 5.85 6.17 5.84
    Nov 6, 2023 6.11 0.28 4.80% 5.83 6.12 5.81
    Nov 3, 2023 5.62 0.35 6.64% 5.27 5.75 5.23

    Talis Biomedical Corporation Events

    Time (UTC) Country Event
    Wednesday, March 20, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Talis Biomedical Corp Earnings Release
    Q4 2023 Talis Biomedical Corp Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 4.812 8.193 10.938 3.977 2.39
    Revenue 4.812 8.193 10.938 3.977 2.39
    Total Operating Expense 119.951 200.009 102.122 30.676 23.82
    Selling/General/Admin. Expenses, Total 40.729 42.418 13.103 6.864 5.432
    Research & Development 70.831 157.591 89.019 23.812 18.388
    Operating Income -115.139 -191.816 -91.184 -26.699 -21.43
    Interest Income (Expense), Net Non-Operating 0.054 0.042 0.093
    Other, Net 2.127 -0.22 0 -0.817 0
    Net Income Before Taxes -113.012 -192.036 -91.13 -27.474 -21.337
    Net Income After Taxes -113.012 -192.036 -91.13 -27.474 -21.337
    Net Income Before Extra. Items -113.012 -192.036 -91.13 -27.474 -21.337
    Net Income -113.012 -192.036 -91.13 -27.474 -21.337
    Total Adjustments to Net Income 0 53.856 0
    Income Available to Common Excl. Extra. Items -113.012 -192.036 -91.13 26.382 -21.337
    Income Available to Common Incl. Extra. Items -113.012 -192.036 -91.13 26.382 -21.337
    Diluted Net Income -113.012 -192.036 -91.13 26.382 -21.337
    Diluted Weighted Average Shares 1.77555 1.51043 1.5654 1.5654 1.5654
    Diluted EPS Excluding Extraordinary Items -63.6491 -127.14 -58.215 16.8532 -13.6304
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -61.6215 -127.14 -58.215 16.8532 -13.6304
    Cost of Revenue, Total 8.391
    Gross Profit -3.579
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.581 1.218 0.257 0.796 0.572
    Revenue 0.581 1.218 0.257 0.796 0.572
    Total Operating Expense 16.972 20.215 28.37 27.582 27.845
    Selling/General/Admin. Expenses, Total 6.41 6.399 10.796 8.825 9.178
    Research & Development 10.555 13.796 15.242 17.521 17.365
    Operating Income -16.391 -18.997 -28.113 -26.786 -27.273
    Other, Net 1.357 1.166 1.184 0.765 0.262
    Net Income Before Taxes -15.034 -17.831 -26.929 -26.021 -27.011
    Net Income After Taxes -15.034 -17.831 -26.929 -26.021 -27.011
    Net Income Before Extra. Items -15.034 -17.831 -26.929 -26.021 -27.011
    Net Income -15.034 -17.831 -26.929 -26.021 -27.011
    Income Available to Common Excl. Extra. Items -15.034 -17.831 -26.929 -26.021 -27.011
    Income Available to Common Incl. Extra. Items -15.034 -17.831 -26.929 -26.021 -27.011
    Diluted Net Income -15.034 -17.831 -26.929 -26.021 -27.011
    Diluted Weighted Average Shares 1.81729 1.78781 1.79148 1.7765 1.77468
    Diluted EPS Excluding Extraordinary Items -8.27277 -9.97366 -15.0317 -14.6473 -15.2202
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -8.27277 -9.97366 -13.0222 -14.6473 -15.2202
    Cost of Revenue, Total 0.007 0.02 2.332 1.236 1.302
    Gross Profit 0.574 1.198 -2.075 -0.44 -0.73
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 133.282 236.115 188.724 24.107 9.336
    Cash and Short Term Investments 130.191 232.545 138.483 21.604 6.895
    Cash 130.191 232.545 138.483 21.604 6.895
    Total Receivables, Net 0.308 0.183 0.471 1.806 1.997
    Accounts Receivable - Trade, Net 0.233 1.806 1.997
    Prepaid Expenses 2.783 3.387 15.12 0.697 0.444
    Total Assets 169.29 265.828 198.405 25.733 11.378
    Property/Plant/Equipment, Total - Net 34.232 23.435 9.681 1.535 1.811
    Property/Plant/Equipment, Total - Gross 47.054 27.427 12.679 3.77 3.321
    Accumulated Depreciation, Total -12.822 -3.992 -2.998 -2.235 -1.51
    Other Long Term Assets, Total 1.776 6.278 0 0.091 0.231
    Total Current Liabilities 12.672 19.106 16.026 4.037 3.368
    Accounts Payable 3.768 5.122 4.906 1.566 1.509
    Accrued Expenses 8.904 12.904 10.399 1.908 1.473
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.08 0.721 0.563 0.386
    Total Liabilities 42.551 31.851 16.031 4.118 3.684
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 29.879 12.745 0.005 0.081 0.316
    Total Equity 126.739 233.977 182.374 21.615 7.694
    Redeemable Preferred Stock 0.003 0.003 290.945 42.755 59.696
    Common Stock 0.003 0.003 0 0 0
    Additional Paid-In Capital 604.687 598.913 64.335 60.636 2.3
    Retained Earnings (Accumulated Deficit) -477.954 -364.942 -172.906 -81.776 -54.302
    Total Liabilities & Shareholders’ Equity 169.29 265.828 198.405 25.733 11.378
    Total Common Shares Outstanding 1.78648 1.76062 1.5654 1.5654 1.5654
    Total Preferred Shares Outstanding 29.8637 29.8637 29.8637 29.8637 29.8637
    Other Current Assets, Total 0 34.65
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 89.532 101.965 115.588 133.282 150.377
    Cash and Short Term Investments 87.996 98.2 112.959 130.191 143.783
    Cash 87.996 98.2 112.959 130.191 143.783
    Total Receivables, Net 0.005 0.532 0.127 0.308 0.433
    Accounts Receivable - Trade, Net
    Prepaid Expenses 1.531 2.223 1.492 2.783 4.134
    Other Current Assets, Total 1.01 1.01
    Total Assets 107.228 123.076 133.053 169.29 194.094
    Property/Plant/Equipment, Total - Net 16.154 19.569 15.923 34.232 41.941
    Other Long Term Assets, Total 1.542 1.542 1.542 1.776 1.776
    Total Current Liabilities 8.45 9.262 11.18 12.672 11.378
    Accounts Payable 2.697 2.491 3.871 3.768 4.111
    Accrued Expenses 5.753 6.771 7.309 8.904 7.267
    Notes Payable/Short Term Debt 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 25.672 26.91 22.929 42.551 41.708
    Total Long Term Debt 0 0 0 0
    Total Equity 81.556 96.166 110.124 126.739 152.386
    Redeemable Preferred Stock 0.003 0.003 0.003 0.003 0.003
    Common Stock 0 0.003 0.003 0.003
    Additional Paid-In Capital 608.054 606.982 605.903 604.687 603.405
    Retained Earnings (Accumulated Deficit) -526.501 -510.819 -495.785 -477.954 -451.025
    Total Liabilities & Shareholders’ Equity 107.228 123.076 133.053 169.29 194.094
    Total Common Shares Outstanding 1.81914 1.81903 1.79126 1.78648 1.78555
    Total Preferred Shares Outstanding 29.8637 29.8637 29.8637 29.8637 29.8637
    Other Liabilities, Total 17.222 17.648 11.749 29.879 30.33
    Total Inventory 2.027
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -113.012 -192.036 -91.13 -27.474 -21.337
    Cash From Operating Activities -100.136 -171.384 -87.024 -24.326 -20.943
    Cash From Operating Activities 8.83 1.578 0.763 0.726 0.647
    Non-Cash Items 11.732 10.25 4.294 1.782 0.679
    Changes in Working Capital -7.686 8.824 -0.951 0.64 -0.932
    Cash From Investing Activities -1.615 -2.866 -8.201 -0.578 -0.533
    Capital Expenditures -1.615 -2.866 -8.201 -0.578 -0.533
    Cash From Financing Activities 0.406 234.429 246.754 39.613 0.008
    Issuance (Retirement) of Stock, Net 0.406 234.429 248.205 24.613 0.008
    Issuance (Retirement) of Debt, Net 0 15 0
    Net Change in Cash -101.345 60.179 151.529 14.709 -21.468
    Financing Cash Flow Items 0 -1.451
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -17.831 -113.012 -86.083 -60.062 -33.051
    Cash From Operating Activities -16.465 -100.136 -86.593 -65.771 -43.758
    Cash From Operating Activities 0.174 8.83 5.268 1.343 0.363
    Non-Cash Items 1.968 11.732 6.039 3.798 1.954
    Changes in Working Capital -0.776 -7.686 -11.817 -10.85 -13.024
    Cash From Investing Activities -0.024 -1.615 -1.566 -0.706 -0.507
    Capital Expenditures -0.024 -1.615 -1.566 -0.706 -0.507
    Cash From Financing Activities 0.033 0.406 0.406 0.314 0.314
    Issuance (Retirement) of Stock, Net 0.033 0.406 0.406 0.314 0.314
    Net Change in Cash -16.456 -101.345 -87.753 -66.163 -43.951
    Financing Cash Flow Items

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Talis Biomedical Corporation Company profile

    About Talis Biomedical Corp

    Talis Biomedical Corporation. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The Company is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The Company is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Talis Biomedical Corp revenues decreased 25% to $8.2M. Net loss increased from $91.1M to $192M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$3.88 to -$7.30.

    Industry: Biotechnology & Medical Research (NEC)

    1100 Island Drive
    Suite 101
    REDWOOD CITY
    CALIFORNIA 94065
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    BTC/USD

    38,882.05 Price
    +0.080% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.62 Price
    +0.410% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading